RedHill Biopharma: Net revenues for 2017 totaled $4M, and met our expectations. We expect Redhill to raise capital in anticipation of its announcement of top-line Phase III results for Crohn’s disease, expected in mid-2018; Price target raised to NIS 2.59

• Post author:jaimeuss_admin
• Post published:17 בSeptember 2018
• Post category:Research
• Post comments:0 Comments

Continue ReadingRedHill Biopharma: Net revenues for 2017 totaled $4M, and met our expectations. We expect Redhill to raise capital in anticipation of its announcement of top-line Phase III results for Crohn’s disease, expected in mid-2018; Price target raised to NIS 2.59

BiolineRx: Continued advancement and execution of BiolineRx’s lead oncology project – BL-8040; sufficient funds to support clinical strategy; stock target price remains at NIS 5.15

• Post author:jaimeuss_admin
• Post published:30 בAugust 2018
• Post category:Research
• Post comments:0 Comments

Continue ReadingBiolineRx: Continued advancement and execution of BiolineRx’s lead oncology project – BL-8040; sufficient funds to support clinical strategy; stock target price remains at NIS 5.15